최상호 (울산의대,서울아산병원) | 한빛사논문 > 한빛사

한빛사논문

조회244

울산의대,서울아산병원

CV File 115 kb

Emerg. Infect. Dis, Jun 2024, 30 (6) | https://doi.org/10.3201/eid3006.230670 Severe Human Parainfluenza Virus Community- and Healthcare-Acquired Pneumonia in Adults at Tertiary Hospital, Seoul, South Korea, 2010-2019

Joung Ha Park,¹ Sang-Bum Hong,¹ Jin Won Huh, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Heungsup Sung, Kyung Hyun Do, Sung-Han Kim, Sang-Oh Lee, Yang Soo Kim, Chae-Man Lim, Younsuck Koh, Sang-Ho Choi

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea (J.H. Park); University of Ulsan College of Medicine Asan Medical Center, Seoul, South Korea (S.-B. Hong, J.W. Huh, J. Jung, M.J. Kim, Y.P. Chong, H. Sung, K.H. Do, S.-H. Kim, S-.O. Lee, Y.S. Kim, C.-M. Lim, Y. Koh, S.-H. Choi)

¹These authors contributed equally to this article.

Address for correspondence: Sang-Ho Choi

Abstract

The characteristics of severe human parainfluenza virus (HPIV)-associated pneumonia in adults have not been well evaluated. We investigated epidemiologic and clinical characteristics of 143 patients with severe HPIV-associated pneumonia during 2010-2019. HPIV was the most common cause (25.2%) of severe virus-associated hospital-acquired pneumonia and the third most common cause (15.7%) of severe virus-associated community-acquired pneumonia. Hematologic malignancy (35.0%), diabetes mellitus (23.8%), and structural lung disease (21.0%) were common underlying conditions. Co-infections occurred in 54.5% of patients admitted to an intensive care unit. The 90-day mortality rate for HPIV-associated pneumonia was comparable to that for severe influenza virus-associated pneumonia (55.2% vs. 48.4%; p = 0.22). Ribavirin treatment was not associated with lower mortality rates. Fungal co-infections were associated with 82.4% of deaths. Clinicians should consider the possibility of pathogenic co-infections in patients with HPIV-associated pneumonia. Contact precautions and environmental cleaning are crucial to prevent HPIV transmission in hospital settings.

논문정보

형식Review Paper
게재일2024년 06월 (BRIC 등록일 2024-06-13)
연구진국내 연구진
분야 의약학 > 응용의학

댓글 작성 로그인

CV 열람하기

연락처 보기